Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is for adult patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma who have no remaining standard treatment options, and it evaluates the safety, tolerability, and dosing of the investigational drug LB-LR1109, administered intravenously.

ClinicalTrials.gov ID: NCT06332755

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced NSCLC featuring EGFR or HER2 mutations, who have progressed on or are intolerant to existing therapies, and investigates FWD1509 MsOH, an oral tyrosine kinase inhibitor targeting EGFR and HER2 mutations, including exon 19 deletions, L858R, T790M, and EGFRex20ins.

ClinicalTrials.gov ID: NCT05068024

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients with advanced solid tumors, including non-small cell lung cancer and gastric adenocarcinoma, to evaluate the safety and efficacy of BAY2965501, a DGKζ inhibitor targeting diacylglycerol kinases to enhance T-cell-mediated anti-tumor activity, both as monotherapy and in combination with pembrolizumab and platinum-based chemotherapy. Participants must have an ECOG performance status of 0-1 and meet specific disease criteria, with exclusions for primary CNS malignancies or uncontrolled brain metastases.

ClinicalTrials.gov ID: NCT05614102

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced/metastatic solid tumors, exploring BI-1910, a monoclonal antibody targeting TNFR2 to activate T and NK cells, alone and in combination with pembrolizumab, particularly for those who have progressed after or are ineligible for standard therapies.

ClinicalTrials.gov ID: NCT06205706

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets patients with stage IV or recurrent NSCLC resistant to anti-PD1 therapy, using a combination of C-TIL051 (engineered tumor-infiltrating lymphocytes), NKTR-255 (IL-15 receptor agonist), and Pembrolizumab to enhance immune response. Participants must have adenocarcinoma or squamous histology, measurable disease, and no prior PD1/PDL1 inhibitor treatment for metastatic disease.

ClinicalTrials.gov ID: NCT05676749

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is enrolling patients with advanced-stage solid tumors, including HER2-mutant non-small cell lung cancer and HER2-positive metastatic breast cancer, to evaluate the safety and efficacy of ELVN-002, a novel oral tyrosine kinase inhibitor targeting HER2 and multiple HER2 mutations, as a monotherapy and in combination with standard treatments.

ClinicalTrials.gov ID: NCT05650879

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates dostarlimab, an anti-PD-1 monoclonal antibody, in adults with advanced solid tumors who have progressed despite prior treatments, focusing on specific cohorts such as endometrial cancer, non-small cell lung cancer, ovarian cancer, and tumors with mismatch repair deficiencies. Participants should have limited viable treatment options.

ClinicalTrials.gov ID: NCT02715284

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is designed for adult patients with EGFR-positive advanced solid tumors that have progressed after systemic therapy, focusing on assessing the safety and optimal dosing of the investigational drug DK210, an EGFR-targeting agent, administered alone or with standard therapies.

ClinicalTrials.gov ID: NCT05704985

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory non-small cell lung cancer, assessing the safety and efficacy of TUB-040, an antibody-drug conjugate targeting NaPi2b with a topoisomerase I inhibitor, administered every three weeks.

ClinicalTrials.gov ID: NCT06303505

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial evaluates the investigational antibody-drug conjugate XB010, which targets the 5T4 antigen to inhibit tumor growth, in adults with locally advanced or metastatic solid tumors who lack alternative treatment options; it assesses XB010 as both a monotherapy and in combination with pembrolizumab across various tumor types including non-small cell lung cancer, hormone-receptor-positive and triple-negative breast cancer, head and neck, and esophageal squamous cell cancers.

ClinicalTrials.gov ID: NCT06545331